Silverarc Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Silverarc Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55M	Buy	206,234 +81,576	+65%	+$19.1M	5.72%	1
2026 Q1	$28.5M	Buy	124,658 +75,430	+153%	+$16.9M	2.91%	12
2025 Q4	$10.5M	Sell	49,228 -4,326	-8%	-$893K	1.46%	22
2025 Q3	$10.6M	Sell	53,554 -32,998	-38%	-$6.15M	1.44%	23
2025 Q2	$14.9M	Buy	86,552 +10,801	+14%	+$1.76M	2.75%	15
2025 Q1	$11.8M	Buy	75,751 +24,260	+47%	+$3.47M	2.41%	13
2024 Q4	$7.09M	Buy	51,491 +46,491	+930%	+$6.11M	1.55%	22
2024 Q3	$747K	Buy	+5,000	New	+$675K	0.17%	61
2023 Q1	–	Sell	-23,151	Closed	-$2.83M	–	76
2022 Q4	$2.83M	Buy	23,151 +18,151	+363%	+$2.11M	0.81%	43
2022 Q3	$516K	Buy	+5,000	New	+$474K	0.17%	68
2022 Q2	–	Sell	-25,000	Closed	-$1.43M	–	72
2022 Q1	$1.43M	Buy	+25,000	New	+$2.9M	0.59%	42
2021 Q3	–	Sell	-5,599	Closed	-$737K	–	87
2021 Q2	$737K	Sell	5,599 -13,095	-70%	-$1.74M	0.33%	71
2021 Q1	$2.41M	Buy	18,694 +1,138	+6%	+$173K	1.31%	29
2020 Q4	$2.93M	Buy	+17,556	New	+$2.9M	1.7%	21

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Silverarc Capital Management's ASND Position: Q2 2026 in Review

Silverarc Capital Management increased its Ascendis Pharma A/S (ASND) stake by 65% in Q2 2026, buying an estimated $19.1M and bringing the position to 206,234 shares worth $55M. The position accounts for 5.72% of the portfolio, ranked #1.

Silverarc Capital Management first reported a position in ASND in Q4 2020 and has held it in 14 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Silverarc Capital Management held 206,234 shares of Ascendis Pharma A/S worth $55M as of Q2 2026.
Silverarc Capital Management bought 81,576 Ascendis Pharma A/S shares in Q2 2026, an estimated $19.1M.
Ascendis Pharma A/S made up 5.72% of Silverarc Capital Management's portfolio in Q2 2026, its #1 holding.
Silverarc Capital Management first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 14 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.